New data highlights the impact of Iqirvo on fatigue, says Ipsen

French drugmaker Ipsen (Euronext: IPN) today announced new data from two late-breaking presentations on Iqirvo (elafibranor) during the European Association for the Study of the Liver congress.
Additional analyses from the ELATIVE study (LBP-027) suggest that patients with primary biliary cholangitis (PBC) treated with Iqirvo had greater improvements in fatigue compared to placebo after 52 weeks, as measured by both the PROMIS Fatigue Short Form 7a questionnaire (42.9% Iqirvo versus 31.3% placebo) and PBC-40 fatigue domain (22.6% Iqirvo versus 15.4% placebo).

Among patients with moderate-to-severe fatigue at baseline, more than twice as many patients treated with Iqirvo (66.7%) achieved clinically meaningful improvements compared to placebo (31.3%). Importantly, the data suggest that the positive effect of IQIRVO on fatigue occurs independently of its effect on pruritus.

Iqirvo won regulatory approval last year, first in the USA in June, the European Union in September and the UK in October. Iqirvo was licensed from fellow France-based Genfit (Euronext: GNFT).